Mizuho Rates ICON Public (ICLR) buy, $190 Price Target

Analyst Ann Hynes at Mizuho keeps a buy rating and a $190 price target on ICON Public Limited Company, aligning with broader sentiment on the healthcare stock, a 9.83% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 10:01 AM EDT · Updated Jun 30, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Mizuho rated ICON Public Limited Company ($ICLR) "buy" with a $190 price target on June 26, 2026.

Since the rating, $ICLR is up 0.6% after 1 week, down 0.6% after 1 month and up 0.2% to date (from the $169.86 close on Jun 26, 2026).

ICLR ICON Public Limited Company

$170.18 -9.80% year to date

Daily close · Oct 16, 2026

Key Points

Mizuho reiterated its buy rating on ICON Public Limited Company with a $190 price target on June 26, 2026.
Mizuho's $190 price target implies 9.83% upside from ICON Public Limited Company's ($ICLR) current $172.99 share price.
The stock trades near $172.99, positioned above both its 50-day moving average of $167.30 and its 200-day moving average of $147.20.
Wall Street maintains a general buy consensus on the company with a mean target price of $185.25 across 16 analysts.

Get $ICLR trade alerts by text

We text you when insiders, Congress or big funds trade $ICLR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ICON Public Limited Company alert may contain errors. Disclosures

Mizuho Keeps Buy Outlook on ICON Public Limited Company

Mizuho reaffirmed its positive stance on ICON Public Limited Company (NasdaqGS: ICLR) on June 26, 2026. Analyst Ann Hynes kept a buy rating on the shares alongside a $190 price target. This update sits among several recent moves from major financial firms tracking the clinical research sector.

Analyst rating track record

Mizuho vs. the S&P 500

YTD return -31.31% hypothetical

All-time return -42.89% S&P 500 +14.08%

vs. S&P 500 -56.97% behind the index

Hypothetical returns from Mizuho's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

Wall Street firms have kept busy updating their views on ICLR through the middle of the year. On September 18, 2026, Citigroup maintained a neutral rating while adjusting its price target to $175 from $180, following an earlier July 31 update where it held a neutral stance with a $180 target. Truist Securities also weighed in on July 31, 2026, by reiterating a buy rating and setting a $209 price target, building on its earlier upgrade to a buy with a $207 target on June 30, 2026. Back on June 26, 2026, alongside Mizuho's note, Citigroup kept a neutral rating with a $165 target, BMO Capital maintained an outperform rating with a $187 target, and Barclays kept an equal-weight rating with a $175 target. Across the broader analyst community, the stock holds a consensus recommendation of buy with 16 experts weighing in, leading to a mean target price of $185.25.

Stock Price Trends and Valuation

Shares of ICON changed hands around $172.99. The stock has experienced a wide trading band over the past year, falling as low as $66.57 and climbing as high as $203.91. Current levels put the share price above its 50-day moving average of $167.30 and well past its 200-day moving average of $147.20. The company carries a market capitalization of $13.08 billion and a forward price-to-earnings ratio of 14.37, while its trailing P/E stands at 256.89 due to lower recent GAAP earnings per share of $0.66.

12-month forecast

$ICLR price target

ICON Public Limited Company daily closes and this analyst's $190 target. Not advice.

Clinical Research Services Provider

Headquartered in Dublin, Ireland, ICON Public Limited Company operates as a clinical research organization that helps drug and medical device developers run clinical trials. The firm handles everything from early compound selection and Phase I studies to large-scale Phase IV testing, laboratory work, and post-market safety tracking. Its clients span pharmaceutical, biotechnology, and government healthcare organizations worldwide.

What to Watch Next for ICLR

Investors tracking the healthcare provider will look toward the company's next earnings report, scheduled for October 21, 2026, for updated revenue and margin details. Analysts will watch whether the firm can build on its recent revenue growth of 1.2% while managing operating expenses.